Laparoscopic Single Anastomosis Sleeve Ileal Bypass Versus Laparoscopic Sleeve Gastrectomy for Morbid Obesity

Sponsor
Oslo University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05611697
Collaborator
(none)
220
2
2
83
110
1.3

Study Details

Study Description

Brief Summary

This study will compare two bariatric surgical interventions in terms of weight loss, gastroesophageal reflux, and effects on obesity-related comorbid conditions in morbidly obese patients.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Single anastomosis sleeve ileal bypass
  • Procedure: Sleeve gastrectomy
N/A

Detailed Description

Sleeve gastrectomy is an established therapeutic option for morbidly obese patients without preexisting gastroesophageal reflux disease. The novel single anastomosis sleeve ileal bypass (SASI) procedure is already introduced in Norway at a private high-volume bariatric hospital. The purpose of this study is to evaluate the effects of SASI in comparison to an established bariatric procedure, i.e. sleeve gastrectomy. The primary end point is 2-year changes in BMI after sleeve gastrectomy and SASI.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
220 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients are randomized in a 1:1 ratio to sleeve gastrectomy or SASI. The randomization list will contain block sizes of 4 and 6 in random order, stratified by study center.Patients are randomized in a 1:1 ratio to sleeve gastrectomy or SASI. The randomization list will contain block sizes of 4 and 6 in random order, stratified by study center.
Masking:
Single (Participant)
Masking Description:
Patients are allocated to surgical treatment 2 weeks before surgery and blinded to treatment allocation until the first postoperative day.
Primary Purpose:
Treatment
Official Title:
Laparoscopic Single Anastomosis Sleeve Ileal Bypass Versus Laparoscopic Sleeve Gastrectomy for Morbid Obesity: A Randomized Trial
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2026
Anticipated Study Completion Date :
Dec 1, 2029

Arms and Interventions

Arm Intervention/Treatment
Experimental: Single anastomosis sleeve ileal bypass

A Single anastomosis sleeve ileal bypass procedure is performed.

Procedure: Single anastomosis sleeve ileal bypass
The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
Other Names:
  • SASI
  • Active Comparator: Sleeve gastrectomy

    A sleeve gastrectomy procedure is performed.

    Procedure: Sleeve gastrectomy
    In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.

    Outcome Measures

    Primary Outcome Measures

    1. Changes in body-mass index (BMI) [2 year]

      Weight in kilograms divided by the square of the height in meters after sleeve gastrectomy and SASI.

    Secondary Outcome Measures

    1. Change in prevalence of esophagitis. [2 year]

      Changes in the prevalence of esophagitis as evaluated by upper endoscopy.

    2. Change in prevalence of gastroesophageal reflux disease. [2 year]

      Changes in the prevalence of gastroesophageal reflux disease as evaluated by 24-hour pH measurements.

    3. Complications [6 weeks (100 days for deaths), 2 year, 5 year]

      Complications during surgery, postoperative complications (within 6 weeks [100 days for deaths]) as defined by the Accordion severity grading system and long-term complications.

    4. Obesity-related comorbid conditions. [2 year, 5 year]

      Changes in obesity-related comorbid conditions.

    5. Vitamin concentrations [2 year, 5 year]

      Changes in vitamin levels (A, B1, B6, B9, B12, C, D, K).

    6. Health-related quality of life [2 year, 5 year]

      Short-Form (36) health survey version 2.0

    7. Obesity-related symptoms [2 year, 5 year]

      Obesity-related Problem scale

    8. Gastrointestinal symptoms [2 year, 5 year]

      GSRS

    9. Gastroesophageal reflux disease symptoms [2 year, 5 year]

      GERDq

    10. Bowel habits [2 year, 5 year]

      Bowel habit questionnaire

    11. Revisional surgery [2 year, 5 year]

      Revisional surgery rates in the two groups.

    12. Long-term changes in BMI [5 years]

      BMI (weight in kilograms divided by the square of the height in meters) after sleeve gastrectomy and SASI.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Morbid obesity at referral for bariatric surgery (i.e. a body-mass index [BMI] of ≥35 kg/m2 with obesity-related comorbid conditions or ≥40 kg/m2 with or without such comorbidities).

    2. Age 20-60 years.

    3. Previous failed attempts of weight loss.

    4. Norwegian speaking patients.

    Exclusion Criteria:
    1. BMI ≥55 kg/m2.

    2. A history of major abdominal or bariatric surgery (excluding appendectomy, cholecystectomy, and sectio).

    3. Established disabling cardiopulmonary disease, ongoing treatment for cancer, long-term steroid use, and conditions believed to be associated with poor adherence after surgery.

    4. Previous or current gastroesophageal reflux symptoms with daily use of antireflux medication. Patients are also excluded if preoperative manometry identifies a hiatal hernia (>3cm in axial length) or if preoperative upper endoscopy identifies esophagitis grade C or D (LA classification), peptic stricture, Barrett's esophagus, or esophageal carcinoma.

    5. Achalasia

    6. Pregnancy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Morbid Obesity Center, Vestfold Hospital Trust Tønsberg Vestfold Norway 3103
    2 Oslo University Hospital Oslo Norway 4950

    Sponsors and Collaborators

    • Oslo University Hospital

    Investigators

    • Principal Investigator: Torgeir T Søvik, MD, PhD, Oslo University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Torgeir Søvik, Principal Investigator, Oslo University Hospital
    ClinicalTrials.gov Identifier:
    NCT05611697
    Other Study ID Numbers:
    • 319260
    First Posted:
    Nov 10, 2022
    Last Update Posted:
    Nov 10, 2022
    Last Verified:
    Nov 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Torgeir Søvik, Principal Investigator, Oslo University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 10, 2022